Nektar Therapeutics (NKTR) Earnings Call Transcript & Summary
May 6, 2021
Earnings Call Speaker Segments
Jennifer Ruddock
executiveThanks, Crystal, and good afternoon to all of you — we appreciate you being with us today. Joining us on this call are our President and CEO, Howard Robin; our COO and CFO, Gil Labrucherie; Dr. Jonathan Zalevsky, who serves as our Chief of Research and Development; and our Interim CMO and Head of Development, Dr. Brian Kotzin. During this call, we anticipate making forward-looking statements about our business, including clinical trial enrollment and results, the timing of and plans for upcoming clinical trials, the timing of and plans for upcoming presentations of clinical data, how our drug candidates might perform therapeutically, the outcomes of and plans for regulatory actions and decisions by health authorities, estimates and predictions concerning how the COVID-19 pandemic will affect our business and our clinical trials, financial guidance, and certain other statements about our business's future. Since forward-looking statements concern the future, they carry inherent uncertainties and risks that are hard to predict, and many of them lie beyond our control. Significant risks and uncertainties appear in the Form 10-K filed on February 26, 2021, which you can access at sec.gov. We assume no obligation to update any of these forward-looking statements, whether because of new information, future developments, or otherwise. A webcast of today's call will be posted on the IR page of Nektar's website at nektar.com. Before I pass the call to Howard, I want to note that because we are dialing in from various locations today, I will moderate the Q&A portion for our team, allowing us to steer clear of technical problems during that portion. Thank you for your patience. Having said that, I'd like to turn the call over to our President and CEO, Howard Robin. Howard?
Howard Robin
executiveAppreciate it, Jennifer, and thanks to all of you for being with us on today's call. As we kicked off 2021, we had a robust pipeline of candidates in immuno-oncology and immunology, running the gamut from Phase I through Phase III development, and we anticipate a consistent flow of important data readouts starting in the latter part of this year. These datasets could put Nektar on a fresh path and reshape how a variety of tumor types in autoimmune disease are treated. Every investigational medicine we have brings its own unique worth and allows us to reach broader groups of patients we might be able to help. Our trailblazing efforts in designing innovative cytokine conjugates as therapeutics have established us as a leader in this space, and we keep concentrating our research there as well as in immune science, laying the groundwork for the next round of IND candidates for our company. So let me begin with a quick look at where things stand with BEMPEG, our furthest-along late-stage clinical program and a novel IL-2 pathway agonist, which is in development alongside checkpoint inhibitors, Opdivo or nivolumab and KEYTRUDA or pembrolizumab. When it comes to BEMPEG paired with these checkpoint inhibitors, our approach centers on going after several major frontline and adjuvant solid tumor settings. Melanoma, renal cell carcinoma and bladder cancer together with nivolumab; and head and neck cancer and non-small cell lung cancer together with pembrolizumab. The chance to combine BEMPEG across these tumor settings is substantial — 2020 sales of PD-1 checkpoint inhibitors in these 5 tumor settings exceeded $5 billion. So we feel good about how BEMPEG is placed across multiple registrational studies and about our plans for further strategic late-stage studies. The clinical program we established over the past several years puts us well ahead of others chasing IL-2 programs in cancer. Thanks to our partnership with BMS, we have 5 ongoing registrational studies of BEMPEG with nivo that are moving along well. Our first 3 registrational studies set to read out in the first half of 2022 are the Phase III study in metastatic melanoma, the Phase III study in renal cell carcinoma and the Phase II accelerated approval study in cisplatin-ineligible bladder cancer. Additionally underway are 2 large Phase III trials, further up line, one in adjuvant melanoma and one in muscle invasive bladder cancer. Both indications give us a chance to grow the melanoma and bladder cancer patient populations that might benefit from BEMPEG treatment. Beyond that, BMS is running a Phase II study in renal cell carcinoma for BEMPEG plus nivo with a TKI to set the stage for future development of a TKI-inclusive regimen in the first-line RCC setting. That study is built to follow on their recent successful approval of nivo plus cabo. When it comes to how we're approaching BEMPEG plus PEMBRO, the top priority is to concentrate on the biggest areas where pembrolizumab serves as the gold standard of care — non-small cell lung cancer and head and neck cancer — since those are settings where we can pair BEMPEG with PEMBRO and conduct a comparative trial built for registrational purposes, testing it against PEMBRO as a monotherapy. Back in February, for the first-line head and neck cancer indication, we disclosed 2 distinct collaborations — one alongside SFJ and another alongside Merck — and these let us pre-fund a fresh registrational trial of BEMPEG plus PEMBRO against PEMBRO alone. More recently, 2 competing late-stage trials produced negative data readouts in the first-line setting. Because of that, the competitive landscape has contracted so much that we feel excited about the choice we made and about our capacity to move forward with this trial. In this setting, PEMBRO is now given to more than 70% of patients and has taken the place of the extreme regimen. This trial remains very much on track to begin at the close of Q3 or the start of Q4. We project that this fresh head and neck cancer opportunity might bring in yearly revenues somewhere between $500 million and $800 million worldwide, making it a meaningful value addition to the BEMPEG development growth. Over in non-small cell lung cancer, Nektar is pushing ahead with our own Phase II trial called PROPEL, which examines BEMPEG plus PEMBRO. We've been delighted by the strong interest shown in this trial by top thoracic oncology treatment sites. Although pembrolizumab has extended overall survival for non-small cell lung cancer patients, the benefit it offers is still capped at roughly 2 years; we see a chance to boost that treatment benefit and to create a chemo-sparing regimen for this tumor setting; we intend to conduct our first formal data cut from the initial portion of the trial at some point during the second half of this year. As we follow the doubling in PROPEL, those data will shape our first Phase III registrational trial strategy in non-small cell lung cancer, a setting where we think genuine differentiation is possible with a chemo-sparing regimen. Just to remind everyone, under the BMS agreement, we hold a $1.4 billion filing and milestone approvals for BEMPEG across the U.S., Europe and Japan, and those are contingent on any BEMPEG approval, whether or not that approval comes in combination with nivo. We can receive $625 million for filings and approvals in the first indication, plus $260 million for each of the next 3 indications. Once again, it doesn't matter whether the filing and approval involves a combination with nivo or with PEMBRO. With 6 registrational studies backing possible filings, we have plenty of chances to collect these milestones. Let me now move to NKTR-255, our second major cytokine program in immuno-oncology. For us, this candidate represents an outstanding development opportunity as a proliferator of natural killer cells that has likewise shown it can expand CD8 T cells and memory T cells. The distinctive properties of NKTR-255 give us a chance that might prove even bigger than BEMPEG across various tumor types, since we're advancing this differentiated IL-15 agent through early-stage trials in liquid as well as solid tumors. Our initial Phase I/II clinical trials centered on pairing NKTR-255 with top approved antibodies whose ADCC mechanism—antibody-dependent cellular cytotoxicity—destroys cancer cells and depends on working natural killer cells to function. It's established that sustained natural killer cell expansion via an IL-15 pathway can substantially boost how well those ADCC agents perform. So we're concentrating our earliest clinical work in liquid and solid tumors on proving that administering NKTR-255 alongside such agents delivers greater clinical benefit to patients. For liquid tumors, our combination partners are rituximab and daratumumab. For solid tumors, we're pairing it with cetuximab. Data from our first combinations with these agents will arrive before this year ends, and we're eager to share those results with you. JZ will elaborate shortly on why NKTR-255 has us excited. NKTR-358 is the third cytokine program in our portfolio, under development for autoimmune disease through a partnership with Eli Lilly, targeting a wide spectrum of autoimmune and inflammatory conditions; at present, we expect Lilly to move forward with Phase II studies covering no fewer than 4 indications.
Howard Robin
executiveNKTR-358 was found and created in Nektar's own laboratories. It goes after the interleukin-2 receptor complex within the body, with the goal of driving multiplication of strong inhibitory immune cells called regulatory T cells. Through the activation of those cells, NKTR-358 might be able to restore the immune system to a balanced state. Together with Lilly, our collaborator, we stand as the obvious frontrunner in this area, both in terms of how broad our efforts are and how far along development has come; no other company besides us has reported a multiple dose effect from its agent on T regulatory cells in patients. Brian will go into more detail about this program afterward, but across the past 6 to 9 months we have achieved excellent progress. Our development team handed the clinical program off to Lilly's team without a hitch. At this point Lilly has 4 clinical studies running: a Phase II placebo-controlled study of 280 patients in lupus; a Phase II placebo-controlled study of 200 patients in ulcerative colitis; plus 2 separate Phase Ib studies still ongoing, one in psoriasis and one in atopic dermatitis. More Phase II studies are planned for addition to the program; in lupus and ulcerative colitis by themselves, the chance for NKTR-358 might be quite substantial. At present the top agent for lupus, Benlysta, brings in close to $800 million in global sales, yet a major need exists for newer and improved treatment for these patients, with roughly 750,000 patients in the U.S. currently carrying a lupus diagnosis. Our initial data are extremely promising, and that prompted a big dose-ranging, placebo-controlled trial of NKTR-358 in these patients, which began during Q3 of last year; we expect data from that trial might arrive in 2022. For ulcerative colitis, agents approved today generate about $6 billion annually, with 600,000 patients across the U.S. and Europe by themselves diagnosed with moderate to severe ulcerative colitis; we think there is a chance to serve these patients with a superior potential therapy. Enrollment is now open for the Phase II study in ulcerative colitis, and we look forward to that program moving ahead too. Both we and Lilly, our collaborator, regard NKTR-358 as a possible first-in-class resolution therapeutic that might tackle the fundamental immune system imbalance seen in patients with numerous autoimmune and inflammatory conditions. Last, the economics here are meaningful for NKTR-358, since our royalties under this agreement grow in step with how much we participate in development, which means considerable ownership of an agent undergoing broad development. We take pride in what we have accomplished with this program and are thrilled by the acknowledgment from Lilly, a leader in autoimmunity, that NKTR-358 could potentially assist patients across a wide range of autoimmune and inflammatory conditions. We likewise stay in a very solid financial position to carry out our deep and growing pipeline. We closed the first quarter of 2021 with roughly $1.1 billion in cash and investments. And as you can tell, Nektar has assembled an extraordinarily powerful pipeline of differentiated cytokine therapeutics, which leaves us well placed to create substantial value across multiple therapeutic areas. At this point, I want to hand things over to JZ, who's going to take a bit of time to discuss the major development programs, the data readouts coming in this year, and some other updates too. JZ?
Jonathan Zalevsky
executiveAppreciate that, Howard. I'll begin by covering the BEMPEG program and when we anticipate our registrational trial data to come through. To begin, regarding the first-line metastatic melanoma trial, our collaborator BMS is conducting it, and BMS has said results should be ready somewhere between the latter portion of this year and the opening months of 2022. This research examines BEMPEG combined with nivolumab against nivolumab by itself, and the trial's structure assumes a median progression-free survival, or PFS, for the nivolumab group matching the 6.9 months seen in CheckMate 067. Keep in mind that because PFS is analyzed based on events, several elements—such as how quickly PFS events build up—could affect when the data arrives. Turning to the following trial, which Nektar is conducting, that's the Phase III study in first-line renal cell carcinoma. We anticipate possibly hitting our initial interim analysis on the primary overall survival endpoint at some point during the first half of 2022. And as Howard mentioned before, BMS together with Nektar is pursuing a broad strategy for developing BEMPEG plus nivolumab in this cancer type. BMS is running a Phase I/II RCC trial that pairs BEMPEG plus nivolumab alongside a TKI, letting us measure this regimen against the nivolumab TKI combination, which clears a path toward a TKI-containing approach in RCC that also includes a BEMPEG plus nivolumab doublet. Now, regarding the Phase II trial in first-line cisplatin-ineligible urothelial carcinoma, that study is built to support a possible submission seeking accelerated approval. Its primary endpoints are overall response rate, or ORR, and duration of response, assessed through central radiology review, across roughly 110 cis-ineligible urothelial carcinoma patients whose baseline CPS score is 10 or below, serving as an indicator of PD-L1 expression. For this trial, we aim to reach a median follow-up of 18 months when evaluating duration of response, and we anticipate initial findings from it around the middle of 2022. We also have 2 sizable Phase III trials that extend our prior efforts in urothelial carcinoma and melanoma. The first, our muscle invasive bladder cancer trial, is being conducted by BMS and is enrolling about 540 patients, who will get either BEMPEG plus nivolumab or nivolumab alone in the periadjuvant setting across the 12-month treatment window after surgery. Given the size of this trial, we anticipate the initial data to come in 2024. This trial is additionally intended to act as a confirmatory study supporting a possible accelerated approval in the cis-ineligible urothelial carcinoma setting. The second, the adjuvant melanoma trial, is enrolling roughly 950 patients across a 12-month treatment window following surgery, with event-free survival as an endpoint. That trial is meant to establish BEMPEG as the standard of care for treating melanoma, extending the recent nivolumab approval in this setting. If this trial works, it might substantially expand how many melanoma patients could see a benefit from combining BEMPEG with nivolumab. We also anticipate seeing initial data from this trial during 2024. Per Howard's remarks, initial results from the PROPEL study in non-small cell lung cancer should be reported in the latter half of this year. We've mentioned before that we want at least 2 scans' worth of maturity, or more, among patients receiving treatment, so we can properly gauge the clinical benefit the doublet may offer over time. Those patients will be divided among 3 distinct PD-L1 expression subgroups, and the trial's design aims to demonstrate the advantage of the BEMPEG plus pembrolizumab doublet relative to historical ORR rates seen with single-agent pembrolizumab among efficacy-evaluable patients treated in the less than 1%, 1% to 49%, and greater than or equal to 50% PD-L1 expression subgroups; in non-small cell lung cancer, it's known that how much underlying inflammation exists in the tumor microenvironment strongly influences how well single-agent checkpoint inhibitors like pembrolizumab perform; PD-L1 expressive status is what defines this. And as we've previously discussed, patients in the greater than 50% subgroup gain the most from single-agent pembrolizumab. Because BEMPEG's mechanism targets and boosts the inflammatory state of the tumor microenvironment, we think combining BEMPEG with pembrolizumab in non-small cell lung cancer might enhance the doublet's efficacy across multiple PD-L1 expression subgroups; we also recently added a chemotherapy combination arm to PROPEL so that we could potentially incorporate a doublet plus chemo option into our Phase III strategy. Initial data from PROPEL, along with the additional work we're doing on a doublet combined with chemotherapy, will help us settle on a comprehensive Phase III strategy for BEMPEG in non-small cell lung cancer; and we look forward to sharing data from the BEMPEG plus pembrolizumab double cohort in the second half of 2021. For our new registrational Phase II/III trial in head and neck cancer, we are the sponsor and are nearing finalization of protocol details with the FDA and our collaborators, Merck and SFJ. As Howard said earlier, we remain on track to launch the study in the second half of this year. This 500-patient trial is built to support a possible global registration for the BEMPEG plus pembrolizumab doublet. It features an interim analysis of ORR once the first 200 patients have enrolled. Should ORR clear a prespecified futility boundary, the trial will proceed and the remaining 300 patients will be enrolled into the Phase III portion, with now 500 patients evaluated for the primary endpoints of ORR and overall survival. We're genuinely enthusiastic about what this doublet might achieve in terms of boosting and broadening responses compared with pembrolizumab by itself in this cancer that responds to immune therapy, particularly in light of the results we've observed when BEMPEG is combined with nivolumab in melanoma, which is yet another immune-sensitive cancer. When it comes to head and neck cancer, IL-2 has historically demonstrated activity, with multiple studies published across both the metastatic and adjuvant settings, and developing BEMPEG alongside pembrolizumab in this space is something we're quite thrilled about. On top of that, few late-stage trials are currently underway for this frontline indication. Several other mechanisms have recently failed in the front line. That's why we view this as a distinctive opportunity to position BEMPEG as the first IL-2 mechanism in head and neck cancer. Turning to our COVID-19 study, we're still on schedule to share data from it by the middle of this year. As a reminder, back in November, we launched this Phase Ib randomized, double-blind, placebo-controlled trial, which is assessing single doses of BEMPEG administered to as many as 30 adult patients who have a confirmed COVID-19 infection with mild symptomology. Establishing how well BEMPEG is tolerated in patients with mild COVID-19, evaluating shifts in immune activation over time, and determining a recommended dose for the next study make up the trial's primary objectives. The study is moving along very well, and right now we're enrolling our final dose cohorts of patients.
Jonathan Zalevsky
executiveWe're set to deliver the initial data during the summer, and that should guide how we think about a possible future development route for BEMPEG in this context, given what the current treatment landscape looks like. Now moving on to NKTR-255, which is our IL-15 agonist program. People increasingly appreciate how important natural killer cell biology is when it comes to treating cancer. Through discovering and developing NKTR-255, we've tapped into the abundant biology and therapeutic promise of natural killer cells — this agent engages the entire biology of the IL-15 pathway. On top of that, NKTR-255's broad approach to engaging the IL-15 pathway is able to provide functional activation, and at the same time it brings about homeostatic regulation of the IL-15 response within immune cells — in particular natural killer cells, CD8 T cells, and immune memory subsets. There are many mechanisms that could be paired with the biology NKTR-255 sets off, including targeted agents, cell therapies, and immunological checkpoints too, and the goal is that this might enhance how well those treatments work. Our first clinical trial is focused on targeted antibodies that act through an ADCC mechanism of action. In addition, we have put together a clinical strategy for combining with top targeted antibodies in liquid as well as solid tumors. Later this year, during the back half, we expect to see a number of first data disclosures come through. Those will come from various trials that include dose escalation of NKTR-255 used alone, and also its use alongside at least one targeted antibody. We're eager to present those early results. At SITC 2020 last November, we shared promising first findings from our Phase I/II trial in people whose hematologic malignancies had relapsed or were refractory. Among those with multiple myeloma and non-Hodgkin lymphoma, or NHL, the data indicated that NKTR-255 raises NK cell levels. We also showed further pharmacodynamic shifts that depended on dose, plus encouraging preliminary evidence of clinical activity for NKTR-255 given by itself in those initial dose groups. We're looking at wrapping up the monotherapy dose escalation phase of this trial in the early months of 2021, and results from that escalation are slated for presentation sometime later in the year. Once escalation concludes and we've settled on a recommended Phase II dose, we'll move forward by opening several arms, each enrolling about 20 patients. In one of those arms, we'll be studying NKTR-255 given alone or in combination with rituximab among patients with third-line or later follicular lymphoma or low-grade NHL. Another arm will evaluate NKTR-255 both as a single agent and paired with DARZALEX FASPRO in third-line or greater multiple myeloma. Then there's an arm where NKTR-255 will be tested as monotherapy in NHL patients whose disease had progressed following previously approved CD19 CAR T cell therapies. The next trial we're running looks at pairing NKTR-255 with cetuximab in two separate cohorts of heavily pretreated patients in later lines who suffer from metastatic colorectal cancer or head and neck cancer. Up to 80 participants are being recruited across the U.S. and Europe. As everyone knows, cetuximab on its own yields a response rate that's quite low — about 10% or 15% in such populations — so we aim to do better by bringing NKTR-255 into the mix. Enrollment in this study begins with one arm that combines dose escalation, and at the smallest dose we've already given the drug to patients, with advancement to the next dose level now underway. Because cetuximab alone generated so few responses, as I noted earlier, the unmet need in this later-line population was substantial. Should we show a greater response rate, multiple possible routes forward exist for NKTR-255. Once the combination's dose-finding stage concludes, the trial will expand into separate cohorts for patients with colorectal cancer and head and neck cancer. Initial data from that dose-finding stage should arrive sometime later this year; before passing things to Brian, I want to give a quick update on the next wave of our research activities. In our research and discovery labs, we carry on pioneering efforts grounded in our deep expertise across immune science, cytokine biology and polymer chemistry. Obviously, applying polymer chemistry holds enormous potential for enhancing the pharmacological properties of proteins, cytokines in particular. At Nektar, BEMPEG, NKTR-358, and NKTR-255 provide three distinct examples. Our efforts in this area continue, with attention directed toward further cytokines and the ways they can be used therapeutically in oncology and in other areas. This target space offers substantial opportunity for us, because many cytokines influence a range of biological processes; by leveraging polymer chemistry, we are able to deploy multiple druggability approaches in order to obtain the biological effects we seek. We additionally apply our expertise in immune science to the assessment of other platform modalities beyond polymer chemistry, evaluated individually according to the target and the therapeutic hypothesis. We announced a discovery collaboration with Biolojic Design earlier this year, focused on creating therapeutic antibodies against a highly important targeted immune system. Working together like this, we intend to strengthen our pipeline even more and expand the range of modalities we work with. We're still pushing ahead on the preclinical side with the programs that will support our INDs, and I'm eager to provide more news about those efforts later on. At this point I'll pass things over to Brian, who will walk everyone through the NKTR-358 program in more depth.
Brian Kotzin
executiveThank you, JZ. Just like Howard mentioned before, we're extremely happy about how wide-ranging the NKTR-358 program has become and how much it has moved forward with our collaborator, Eli Lilly. After encouraging results in lupus patients during the prior year, Lilly kicked off the Phase II trial in lupus, and then earlier in this year came the launch of a Phase II trial in ulcerative colitis. On top of that, Lilly keeps pushing ahead with the 2 distinct Phase Ib trials, one in psoriasis and one in atopic dermatitis. There are strong reasons to target the T regulatory cell, or Treg, mechanism when treating autoimmune diseases, and this rationale rests on a large body of evidence showing that a malfunctioning or imbalanced immune system sits beneath the clinical manifestations of these conditions. A number of autoimmune and inflammatory conditions, systemic lupus and ulcerative colitis among them, come with lower Treg counts, diminished Treg activity and/or less IL-2 being produced. Through NKTR-358, we aim to tackle these Treg abnormalities and create an IL-2-like molecule capable of selectively stimulating Tregs more effectively than native low-dose IL-2 does. Information shared during the prior year at both EULAR and the American College of Rheumatology meeting underscored what our approach might achieve. Notably, we observed a profound, dose-dependent rise in Tregs and Treg subsets brought about by NKTR-358 among patients whose lupus was mild-to-moderate. We additionally observed better lupus skin disease activity with NKTR-358; because these data were so exciting, Lilly moved to launch a Phase II trial in lupus involving moderate to severe systemic lupus; within that Phase II lupus trial, which started dosing patients in quarter 3 of 2020, 280 patients are being randomized across 1 of 3 doses of NKTR-358 or placebo, given every 2 weeks across a treatment period lasting 24 weeks. The primary endpoint for this Phase II trial is the percentage of patients who reach a reduction of at least 4 points on the SLE disease activity index, or SLEDAI scale. Standard clinical composite endpoints that lupus studies typically use are included as secondary endpoints as well. We will further characterize pharmacokinetics, pharmacodynamics and immunogenicity among treated patients. Measurements of endpoints will happen at week 24, and our expectation is that the trial finishes within 18 to 24 months. Earlier in this year, Lilly also launched a Phase II randomized placebo-controlled trial among patients with ulcerative colitis that started enrolling patients in quarter 1 of 2021. Just as with lupus, the literature contains substantial evidence regarding the part Tregs play in inflammatory bowel diseases like ulcerative colitis. Lower numbers and diminished functionality of peripheral Treg cells have been documented among these patients, and evidence also exists that an improper balance between functional Tregs and T effector cells within the intestinal microenvironment plays a role in inflammatory lesions. So we're eager to move forward with ulcerative colitis using NKTR-358 and to grow this program alongside our partner, Lilly. During the initial induction period, the trial will assess multiple dose levels through an adaptive design. The study aims to enroll 200 patients in total, and what it measures is the proportion of individuals achieving clinical remission following induction therapy at the 12-week mark. Also, as Howard mentioned previously, we're aware that Lilly intends to keep expanding the development program for NKTR-358. They're planning to launch 2 more Phase II studies over the coming 9 to 12 months, in indications that haven't been revealed yet. We're happy about how quickly Lilly is moving the program forward and their interest in developing this agent across a broad range of inflammatory and autoimmune conditions. Lastly, we're eager for a possible presentation of the ongoing Phase Ib research in psoriasis and atopic dermatitis involving NKTR-358, with results from at least one of those studies expected to be shared at a medical meeting within the next year. At this point, I'll hand the call over to Gil so he can walk through the financials.
Gil Labrucherie
executiveThanks, Brian, and good afternoon to all of you. During this call, I'll walk through our financial guidance for 2021, and for the year it remains the same; we closed out the first quarter in a financial position that was exceptionally strong, holding $1.1 billion in cash and investments. In the quarter, we were happy to share that we formed strategic collaborations with SFJ Pharmaceuticals and Merck. As set out in those agreements, SFJ has committed to provide as much as $150 million in funding for the BEMPEG registrational study in head and neck cancer. And pembrolizumab will be supplied by Merck to Nektar at no cost. Success payments to which SFJ is entitled rest solely on FDA approval of BEMPEG in first-line metastatic melanoma, head and neck cancer, and one additional BEMPEG indication; the risk/reward structure of these collaborations pleases us greatly, since it lets us add yet another very large indication opportunity into the BEMPEG portfolio. Our projected cash usage for 2021 has not changed since our February earnings call, and our plan is still to finish the year holding no less than $750 million in cash and investments. For the full year, our GAAP revenue guidance is likewise unchanged at roughly $100 million for 2021, and it encompasses somewhere between $15 million and $20 million of product sales, plus $80 million and $85 million of noncash royalties; we anticipate recognizing that revenue on a reasonably ratable basis across the year. Our GAAP R&D expense guidance is unchanged for the year as well. We expect 2021 GAAP R&D expense to fall in a range of $450 million to $500 million. A sizable noncash component of about $85 million is part of our R&D guidance, made up of $30 million of noncash development expenses for the BEMPEG head and neck study, which SFJ is funding, yet which will keep being shown as a component of our R&D expense, along with approximately $55 million of noncash depreciation and stock compensation expense. Our G&A expense guidance for 2021 is still expected to land between $120 million and $125 million, and it includes roughly $45 million of noncash depreciation and stock compensation expense. Between $50 million and $60 million of noncash interest expense is anticipated, stemming from the monetization of our royalty streams. On top of that, our nonoperating expense reflects accounting for the contingent success-based payments owed to SFJ as a derivative liability. As time goes on, we will evaluate how likely SFJ is to earn those success payments and record the expense in our income statement, with a matching increase to the derivative liability, using a probability adjusted and weighted discounted cash flow model that we'll look at each quarter. As I went over on our February call, we still expect roughly $15 million of noncash expense tied to the remeasurement of this derivative liability during 2021. And with that, I'll turn the call over for questions. Operator?
Peter Lawson
analystGreat; regarding the PROPEL study in lung, how much data might we potentially see during the second half of this year?
Jennifer Ruddock
executiveThanks, Peter. JZ, would you mind taking this one?
Jonathan Zalevsky
executiveAbsolutely, Peter — JZ here. Thanks for asking. So, as we shared during the JPMorgan update and also earlier in the year, the trial's design calls for roughly 60 patients to be enrolled, split among 3 distinct PD-L1 expression subgroups. Each subgroup contains about 20 patients. Then, as we described toward the end of last year, we observed a genuine uptick in how quickly patients were accruing. We've mentioned this previously: it was tied in large part to lessening COVID intensity across Europe. Many of our sites there brought patients in extremely fast. With these patients, our plan is to track them over a very lengthy period, gathering at minimum 2 scans' worth of data per patient, so we can offer a really rich, mature data set. We're aiming for a presentation in the second half of the year, where we'll share the full scope of data you'd expect from a Phase II study of this kind. For every patient, we'll show response rates, plus all the other response composites — complete response rate, depth of response, duration of response, any time-to-event style endpoints — together with all safety information gathered from patients, and also some biomarkers we collected from available tumor biopsies and whole blood samples. Regarding benchmarks we've discussed when considering a study like this: there's reasonably solid information for single-agent pembrolizumab across the PD-L1 subgroups. In the less than 1% group, single-agent pembro showed about an 8% response rate in KEYNOTE-001. In the 1% to 49% subgroup, single-agent PEMBRO produced a response rate near 15%. And in the greater than 50% group, the response rate came in at 40% to 45%. Those are the sorts of benchmarks to bear in mind when we look at this study's data. Thanks for the question.
Peter Lawson
analystThen I have one more question. That third cohort, the one combining chemotherapy in the PROPEL lung study — when can we expect to see results from it?
Jonathan Zalevsky
executiveRight. Those cohorts have only just begun to be opened. Accrual is therefore in its earliest stages. So results should come later on, at a point well into the coming year.
Jay Olson
analystGiven that nonchemo triplets are looking more and more encouraging, could you say something about how the triple combination of BEMPEG alongside nivo and a TKI might slot into RCC? Also, what about the possibility of pushing a triplet regimen of that kind into earlier lines for non-small cell lung cancer?
Jennifer Ruddock
executiveThanks, Jay. JZ, would you like to field that one?
Jonathan Zalevsky
executiveAlright. Yes, absolutely. Thanks for asking that. So, I believe we have clearly witnessed the genuine effect of combining a TKI with a checkpoint inhibitor in RCC, and there are several instances of this. We have observed it with avelumab plus axi, with PEMBRO plus axi, and then PEMBRO alongside Lenvima — truly some remarkable outcomes. And naturally, cabo plus nivolumab as well. So the chance to introduce a third agent remains, since better response rates, improved durability, and further elevation of the tail of the curve are still needed. That being said, you must weigh all these factors. The RCC space is crowded, and many developments are happening. And then, obviously, you also need to be careful not to excessively increase any toxicity when you begin putting 3 drugs together. But we are extremely enthusiastic about the possibility with BEMPEG plus nivolumab and the TKI, and so is BMS, which explains why this is such a crucial component of our development program. That clinical trial is progressing well. It is enrolling patients. And we believe there is a genuine opportunity in that setting. The other aspect of your question, I think, is also quite provocative, because we are aware that an ongoing study is being conducted nearby — the LEAP study with PEMBRO plus LENVIMA in non-small cell lung cancer. This particular one is really concentrating on the greater than 1% population added on to nivolumab. So once more, that would be a highly interesting trial readout. It is anticipated probably in the early to mid part of the next year. And since that could potentially affect the standard of care in non-small cell lung cancer, once again, it would present an opportunity for a triplet combination, again with the possibility of adding BEMPEG even to that doublet as well.
Jessica Fye
analystI've got several questions about BEMPEG. Let's start with melanoma, then I'll ask a couple about lung. You mentioned that initial data from the first-line melanoma trial could come around the end of the year or in early 2022. Is that timing tied to the ORR interim analysis? Or are you actually talking about a PFS readout? If it's the ORR, when should we expect the PFS results from that trial?
Jennifer Ruddock
executiveJess, it's Jennifer here. I'll handle that one and check whether JZ has anything to add. The melanoma trial is being conducted by BMS, as it happens. So there are two endpoints, ORR and PFS, and they'll be the first to read out. According to how the trial was originally designed, those two endpoints were spaced 4 to 6 months apart. We haven't yet settled with BMS on the way we'll disclose the data. I'd say the best reference point is probably other companies that have run trials with them — how they've handled disclosures and the manner in which they release data. Take the CheckMate 9ER trial, for instance: it came out through a press release. So once again, BMS is the one running this trial, and we'll coordinate closely with them regarding disclosures, but my sense is that no choices have been finalized on that front yet. The original design, though, was ORR first, then PFS, with both assessed by independent review.
Jessica Fye
analystAll right. Then regarding lung, by the time the PROPEL study gets presented, what do you anticipate the typical scan count per patient will be? I recognize you mentioned that every patient has at least 2 scans, but my question is what do you expect that average scan number to be at that point?
Jennifer Ruddock
executiveJZ, would you like to take a shot at this regarding how mature the data is?
Jonathan Zalevsky
executiveRight, Jessica, what we're aiming to do is show mature data. Since the trial kicked off partway through last year, a number of patients have been enrolled longer than others. On top of that, we obviously conduct scans roughly every 9 weeks, so what we're targeting is at least 2 scans for each patient. And once again, the aim is simply to put forward a data set that's rich and interpretable.
Alexandre Bouilloux
analystAlex here, filling in for Difei. I have one more question regarding the lung data that's scheduled to arrive in the second half. You mentioned some benchmarks involving PEMBRO by itself and the ORR rates across the various PD-L1 expressers. Could you share what sort of gap in response rates relative to PEMBRO by itself you would view as promising — something you'd want to advance? And in addition to that, would the choice about whether to advance be one that Merck and Nektar make jointly?
Howard Robin
executiveThank you, Alex. JZ, would you like to take that one?
Jonathan Zalevsky
executiveYeah. Yeah, definitely — those are solid questions. So, like I said, the benchmarks we discussed for single-agent pembrolizumab... The study actually has certain statistical elements designed into it, for instance the Fleming criteria we mentioned earlier; so there are these Fleming-type guidelines, correct, that are built into the trial. But another way to think about it, Alex, is simply approaches that are meaningfully, sort of, different, right, from those benchmarks. So for instance, if you take the 1% to 49% subgroup and you also take BEMPEG's mechanism of action — basically transforming the tumor microenvironment so it resembles a tumor that's like greater than 50% in its kind of PD-L1 status, its interferon gene expression, the amount of CD8 infiltrates and other things like that — we, you could really transform that tumor to boost the efficacy of the combination. So when we examine those benchmarks, we look at things like doubling, for instance, or more the response rate in the less than 1%, for example, tripling it. So in the 20s, the mid-20s relative to an 8% historical in the less than 1%. Those are the sorts of ranges we're considering. And then you also consider the whole totality of the data too, right? We'll examine durability of the responses. And we'll examine time to event like progression and other sorts of components too. Regarding the decision to go to Phase III, keep in mind that we're running the PROPEL study on our own. We're not collaborating with Merck on that trial. And so any decision to move forward to Phase III will rest on the actionability of that data from PROPEL, and that will be our decision, Nektar, to make.
Ben Burnett
analystFantastic. And I just have one quick thing. About the PROPEL study and the group where chemo is being added to the doublet, I suppose, how much latitude do you have when it comes to the BEMPEG dose? And is dose ranging happening here? Or is the particular BEMPEG dose already finalized?
Jonathan Zalevsky
executiveYes. Those really are excellent questions. And so in the PROPEL study, as you're aware, we actually do have the latitude to assess doses, various BEMPEG doses. That therefore covers a dose optimization part that we're conducting with only the doublet across a variety of different tumor types. And so when it comes to chemotherapy, we also have the chance to investigate various dose levels of BEMPEG, though it's genuinely only when needed. I mean, we have a lot of confidence in the dose at which we can combine BEMPEG plus PEMBRO with the chemo.
Daina Graybosch
analystAt the recent ODAC meeting about accelerated approvals for checkpoints, there were two in bladder cancer that caught my attention. I noticed two things that seemed pertinent to what you're planning with BEMPEG in bladder. First, some discussion suggested that avelumab's approval in the first-line maintenance setting for patients who are platinum-sensitive could shrink the unmet need that might support an accelerated approval, possibly among those who can't receive cisplatinum — those cisplatin-ineligible. Second, throughout every ODAC conversation, a recurring theme was FDA discomfort with relying on early-stage checkpoint trials to verify a metastatic accelerated approval. So I'm curious whether you have any perspective, or see any consequences, for your strategy around accelerated approval in bladder cancer.
Jennifer Ruddock
executiveThanks, Daina. JZ, could you take a crack at answering that?
Jonathan Zalevsky
executiveOf course. No, definitely. Daina, I appreciate that question. Those ODAC committee sessions spread across multiple days were quite fascinating, correct, for our whole community; we monitor them very attentively across each of the various tumor types. So — and of course, every one of the points you raise was brought up during discussion. And we'll need to observe, more or less, how the outcome of that ODAC and the ultimate reading of what the FDA concludes regarding the matters they did not actually vote on but which might affect us here; so of course, regarding that initial item, the unmet need may look different given the recent approval you referenced. And something we constantly contend with any time we pursue an accelerated approval is that you truly get assessed on the complete body of data versus whatever standard of care exists at that moment. And therefore, despite the fact that it has shifted from when we launched the trial, that remains the landscape we will be entering. And so our central objective, correct, is to deliver the strongest data set possible in PIVOT-10, demonstrating extremely durable responses, demonstrating a very solid ORR, ideally including a CR rate, the sort we observed in PIVOT-02 when treating those identical patient populations. And then that is nicely counterbalanced by a highly tolerable safety profile, meaning there is a quite sensible risk-benefit picture for the FDA to reach a possible accelerated approval choice. Turning to the following portion, I believe among the genuinely surprising takeaways from that ODAC was, in a sense, how confirmatory trials have performed overall across accelerated approvals; and if you further break that down between solid tumors and liquid tumors, well, it becomes an even more pronounced kind of scenario. So I do believe the FDA's stance on such matters could perhaps be influenced, which was the essence of each of those ODAC meetings. But at this point, we genuinely must simply wait and observe and figure out precisely how it might affect us, if it does at all. I appreciate the thought-provoking questions.
Arlinda Lee
analystRegarding 255, could you discuss — I realize you've covered part of this previously, but about the 2 scans, so essentially if the gap is no less than 2 weeks, then if a patient had responded early, that would count as a confirmed response, and the duration then would be no less than 9 weeks? I'm curious roughly how many patients you believe might have reached that point? Then second, I was wondering about your earlier stage work on other cytokines and platforms outside polymer chemistry. What sorts of things would interest you? And perhaps be additive or complementary to what you currently have?
Jennifer Ruddock
executiveThanks, Arlinda. JZ, would you like to walk through the 255 data that will — that's seen in these studies?
Jonathan Zalevsky
executiveYes. So — yes. I'm not completely certain I grasped the question, Arlinda, but with 255, we're looking at patients who have either heme or solid tumor. Then based on what kind of heme malignancy it is — NHL or multiple myeloma, for instance — the evaluation differs, correct? For instance, for NHL patients we apply Lugano criteria, while for multiple myeloma patients we use the Myeloma Working Group criteria, and in the solid tumor setting we focus more on a RECIST-type approach. That said, we're quite enthusiastic about what the data from both 255 studies are showing us. We can escalate the dose quite effectively. We're observing all the cellular population shifts we'd anticipate. And we're seeing effects both systemic and local in patients who've received NKTR-255. To me, another of the most fascinating and, I'd say, truly profound points is this: keep in mind that many of the multiple myeloma patients we've treated are so advanced that they're dealing with substantial bone marrow dysfunction and damage; and a lot of these individuals already have a broad spectrum of cellular deficiencies stemming from advanced multiple myeloma wearing away at their bone marrow. Yet even among patients whose marrow is compromised, 255 can still raise NK cells and CD8 T cells, generating output despite such advanced disease. So we view those as highly encouraging signals from our IL-15 program agonist. And we're very eager not only to keep these ongoing studies going, but also to share some of that data during the second half of this year. Now, regarding certain things we're pursuing in research and discovery: one item I brought up before is that we — earlier this year, we made public a discovery collaboration with a company named Biolojic Design. They're a firm focused on a rather distinctive form of antibody engineering; in fact they take a computational route; it's an AI-guided approach to protein engineering. I have plenty of enjoyable experience working with antibodies, and the sort of protein engineering Biolojic employs is genuinely compelling. So we're partnering with them to go after very important immunological targets, and we're using an antibody strategy to tackle them. That's one instance of employing a completely different modality; and there are further applications we're exploring too. A number of them entail combining various chemical modifications to proteins, extra chemical modifications to polymers, and non-PEG-based polymers as well, which we can leverage to alter both the geometry of proteins and the multimeric state of proteins so as to trigger differing kinds of signaling. But all of these are the sorts of activities happening in our chemistry labs and at our basic research facility. And I'm excited as those efforts advance, with additional INDs still to come down the road.
Howard Robin
executiveOkay, so first off, thanks to all of you for being here with us today. I also want to express appreciation to the people who work here — their unwavering commitment and steady hard work through these extremely difficult periods have been remarkable. Their focus on moving our clinical trials forward while simultaneously keeping operations running smoothly is truly something, and we feel a great deal of gratitude for what they bring. As I mentioned before, our position is solid, with a robust balance sheet and a significant collection of immuno-oncology and immunology programs, a number of which stand as the furthest along in their respective areas. We are thankful to our investors for the backing they keep giving us, and we look forward to bringing you further news about our programs. We also hope that all of you and your loved ones remain safe and in good health. So, many thanks. I appreciate it.
Operator
operatorThat brings us to the end of today's conference call. We appreciate everyone taking part, and you're free to disconnect at this point. Have a great day, everybody.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Nektar Therapeutics transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Nektar Therapeutics earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Nektar Therapeutics or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.